Imvax Inc. Raises $112 Million in Series C Financing
07/16/20, 11:16 AM
Location
philadelphiaMoney raised
$112 million
Round Type
series c
Imvax, Inc., a clinical-stage biotechnology company whose groundbreaking personalized neo-antigen immunotherapy, IGV-001, is being studied in patients with glioblastoma multiforme (GBM), and whose proprietary technology has the potential to advance care for patients with serious, unmet medical needs in other solid tumor cancers, today announced the completion of a $112 million Series C financing. The round was led by existing investor HP WILD Holding AG, with significant participation from other major shareholders - Ziff Capital Partners, Magnetar Capital, and TLP Investment Partners. This round also includes participation from a new institutional investor – Invus.
Company Info
Company
Imvax, Inc.
Location
philadelphia, pennsylvania, united states
Additional Info
Imvax™ is a clinical-stage biotechnology company committed to revolutionizing immunotherapy for patients with devastating and intractable solid tumor cancers. The company's lead product, IGV-001, which is being studied in patients with newly diagnosed GBM, is a neo-antigen immunotherapy platform that engages both the innate and adaptive elements of the immune system. Other studies have also supported preclinical proof of concept in multiple solid tumors beyond GBM, such as pancreatic, breast and hepatocellular carcinoma.